Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus LORATADINE REDIDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus LORATADINE REDIDOSE.
CLARITIN HIVES RELIEF vs LORATADINE REDIDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in allergic reactions.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
10 mg orally once daily
10 mg orally once daily
None Documented
None Documented
8.4 hours (range 3-20 hours) for loratadine; 28 hours (range 8.8-92 hours) for active metabolite desloratadine, allowing once-daily dosing.
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Renal: ~40% as metabolites, <1% unchanged; Fecal: ~40%; Biliary: minor contribution.
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Category C
Category A/B
Antihistamine
Antihistamine